News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The clinical trial will be conducted at 19 sites with 10,335 participants across India
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Subscribe To Our Newsletter & Stay Updated
